APA (7th ed.) Citation

Labaki, C., Bakouny, Z., Sanglier, T., Schmidt, A., Shim, J., Braun, D., . . . Choueiri, T. (2022). 252P Real-world progression-free survival (rwPFS) and time to next line of therapy (TTNT) as intermediate endpoints for survival in metastatic breast cancer: A real-world experience. Annals of Oncology, 33, S652. https://doi.org/10.1016/j.annonc.2022.07.291

Chicago Style (17th ed.) Citation

Labaki, C., et al. "252P Real-world Progression-free Survival (rwPFS) and Time to Next Line of Therapy (TTNT) as Intermediate Endpoints for Survival in Metastatic Breast Cancer: A Real-world Experience." Annals of Oncology 33 (2022): S652. https://doi.org/10.1016/j.annonc.2022.07.291.

MLA (9th ed.) Citation

Labaki, C., et al. "252P Real-world Progression-free Survival (rwPFS) and Time to Next Line of Therapy (TTNT) as Intermediate Endpoints for Survival in Metastatic Breast Cancer: A Real-world Experience." Annals of Oncology, vol. 33, 2022, p. S652, https://doi.org/10.1016/j.annonc.2022.07.291.